Nexilina (Lacosamide)

Lacosamide, the active ingredient in Nexilina, is a sodium channel modifier presented as an oral tablet for oral use. It treats partial‑onset seizures in patients with epilepsy. GNH USA supplies Nexilina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that works on neuronal sodium channels to control seizure activity. - Partial‑onset seizures: reduces the frequency of focal seizures. - Epilepsy (adjunctive therapy): improves overall seizure control when added to existing regimens. - Refractory focal epilepsy: provides an additional option for patients not responding to other antiepileptic drugs.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Headache: mild to moderate pain in the head region. - Nausea: feeling of stomach upset or urge to vomit. - Fatigue: unusual tiredness or lack of energy. - Blurred vision: temporary visual disturbances. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmia: irregular heart rhythm, including atrial fibrillation. - Severe allergic reactions: anaphylaxis or angioedema. - Liver injury: signs of hepatic dysfunction. - Respiratory depression: marked reduction in breathing effort.

Before initiating therapy with Lacosamide, clinicians should consider several safety measures. - Cardiac assessment: evaluate ECG in patients with known heart disease. - Renal function: monitor kidney function, especially in severe impairment. - Concomitant CNS depressants: assess risk of enhanced sedation when combined with other depressants. - Dizziness counseling: advise patients to avoid driving or operating machinery until they know how the drug affects them. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., carbamazepine): may reduce therapeutic effectiveness. - Other sodium‑channel blockers (e.g., phenytoin): risk of additive toxicity. - QT‑prolonging agents (e.g., sotalol): heightened risk of cardiac arrhythmias. - Alcohol: can potentiate central nervous system depression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise drug concentrations. - Moderate CYP3A4 inducers (e.g., rifampin): may modestly lower efficacy. - Oral contraceptives: possible reduction in hormonal effectiveness. - Antacids: may affect absorption if taken simultaneously. - NSAIDs: increased risk of gastrointestinal irritation.